<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03685942</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH 2017-02</org_study_id>
    <nct_id>NCT03685942</nct_id>
  </id_info>
  <brief_title>Efficacy of Light Therapy Device LUMINETTE® in Major Depressive Disorder</brief_title>
  <acronym>LUMIDEP</acronym>
  <official_title>Efficacy of Light Therapy Device LUMINETTE® in Major Depressive Disorder(LUMIDEP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Psychothérapique de Nancy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LUCIMED</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Psychothérapique de Nancy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of light therapy with LUMINETTE device to usual treatment&#xD;
      (antidepressant drug and psychotherapy) in the treatment of Major Depressive Disorder (MDD).&#xD;
      Half of the participants will receive active light therapy with LUMINETTE device while the&#xD;
      other half will receive placebo light therapy with LUMINETTE placebo device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major depressive disorder (MDD) is a world wide spread disorder. According to the World&#xD;
      health organization, MDD affects more than 300 million people of all ages in the world.&#xD;
      Treatments of MDD include pharmacological treatment and psychotherapy. Pharmacological&#xD;
      treatments, mostly serotonin selective reuptake inhibitors, have a delayed onset of action,&#xD;
      require long-term treatment and have partial efficacy. In fact, only one third of patients&#xD;
      respond to the first antidepressant treatment and two-third after multiple trials. So, there&#xD;
      is a need for new treatment strategy.&#xD;
&#xD;
      Light therapy is a well established non pharmacological treatment of seasonal affective&#xD;
      disorder, a clinical subtype of affective disorder characterized by recurrent episodes of&#xD;
      depression occurring with a seasonal pattern. Patients are exposed to artificial light for a&#xD;
      variable duration and intensity. Although the precise mechanism of bright light therapy&#xD;
      remains unknown, it is thought to act through the eyes by activating the suprachiasmatic&#xD;
      nucleus, the principal circadian pacemaker.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Åsberg depression rating scale (MADRS)</measure>
    <time_frame>week 8</time_frame>
    <description>Rating scale measuring depressive symptoms. Each item is scored from 0 to 3, yielding a total between 0 and 27.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>week 8</time_frame>
    <description>Self reported rating scale measuring quality of sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>week 8</time_frame>
    <description>Self reported rating scale measuring day time sleepiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAM-A)</measure>
    <time_frame>week 8</time_frame>
    <description>Tool measuring the severity of anxiety symptoms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>electroretinogramm</measure>
    <time_frame>at inclusion, week 4,8 and 12</time_frame>
    <description>test that measure the functional activity of the retina</description>
  </other_outcome>
  <other_outcome>
    <measure>Hopkins Verbal Learning Test (HVLT)</measure>
    <time_frame>week 10</time_frame>
    <description>test of verbal Learning and memory</description>
  </other_outcome>
  <other_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>week 10</time_frame>
    <description>screening assessment for detecting cognitive impairment</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroop test</measure>
    <time_frame>week 10</time_frame>
    <description>test assessing the ability to inhibit cognitive interference</description>
  </other_outcome>
  <other_outcome>
    <measure>Trail Making Test (TMT)</measure>
    <time_frame>week 10</time_frame>
    <description>test evaluating executive functions</description>
  </other_outcome>
  <other_outcome>
    <measure>Wechsler Adult Intelligence Scale subtest (WAIS)</measure>
    <time_frame>week 10</time_frame>
    <description>test evaluating memory</description>
  </other_outcome>
  <other_outcome>
    <measure>optical coherence tomography (OCT)</measure>
    <time_frame>inclusion and week 12</time_frame>
    <description>evaluation of retinal structure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Unipolar Depression</condition>
  <arm_group>
    <arm_group_label>active light therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Light therapy 1000 lux daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m., during 8 weeks in addition to usual treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo light therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>People receive usual treatment and use a placebo light therapy device (175 lux) daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m. during 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>active light therapy (LUMINETTE®)</intervention_name>
    <description>light therapy on a portable light visor device</description>
    <arm_group_label>active light therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo light therapy</intervention_name>
    <description>placebo portable light visor device</description>
    <arm_group_label>placebo light therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MDD diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders&#xD;
             I-V (DSM-IV), assessed by means of the Mini Neuropsychiatric International Interview&#xD;
             (MINI).&#xD;
&#xD;
          -  age between 18 and 60 years.&#xD;
&#xD;
          -  affiliation with a welfare scheme.&#xD;
&#xD;
          -  complete information on the study received and written informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diagnosis of a progressive psychiatric disorder (except MDD and anxiety disorder)&#xD;
             according to Axis I of the DSM-IV, assessed by means of the MINI.&#xD;
&#xD;
          -  absence of routine care for MDD.&#xD;
&#xD;
          -  previous or current LT treatment.&#xD;
&#xD;
          -  seasonal affective disorder.&#xD;
&#xD;
          -  high suicide risk, assessed by means of the MINI&#xD;
&#xD;
          -  ongoing neurological disease.&#xD;
&#xD;
          -  retinal pathology.&#xD;
&#xD;
          -  participation in another study.&#xD;
&#xD;
          -  patient impairment leading to difficulty participating or impossibility or inability&#xD;
             to understand the information provided on the study.&#xD;
&#xD;
          -  persons cited in Articles L. 1121-5 to L. 1121-8 of the French Public Health Code:&#xD;
             pregnant women, parturient or breastfeeding mothers, persons deprived of their liberty&#xD;
             by a judicial or administrative decision, persons under psychiatric care under duress,&#xD;
             persons admitted to a health or social establishment for other goals than research,&#xD;
             minors, adults subject to a legal protection, adults who are unable to express their&#xD;
             consent and who are not subject to a legal protection measure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas SCHWITZER</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Psychothérapique de Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eve COSKER</last_name>
    <phone>+33383925034</phone>
    <email>eve.cosker@cpn-laxou.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tatiana DABROWSKI</last_name>
    <phone>+33383925349</phone>
    <email>tatiana.dabrowski@cpn-laxou.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Psychothérapique de Nancy</name>
      <address>
        <city>Laxou</city>
        <zip>54200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eve COSKER</last_name>
      <email>eve.cosker@cpn-laxou.com</email>
    </contact>
    <contact_backup>
      <last_name>Thomas SCHWITZER</last_name>
      <email>thomas.schwitzer@cpn-laxou.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>light therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

